Sarah Cannon Research Institute, the research arm of HCA Healthcare’s global cancer institute, Sarah Cannon, hosted its 21st Annual Scientific Meeting at its headquarters in Nashville, Tenn., on March 9-10, 2018. The meeting gathered experts from across Sarah Cannon Research Institute to discuss the latest advancements in cancer research and care, including breakthroughs in precision medicine, developments in immunotherapy and drug development.
“This year’s Scientific Meeting was a fantastic event,” said David Spigel, MD, Chief Scientific Officer, Director of the Lung Cancer Research Program and Principal Investigator at Sarah Cannon, who welcomed guests and presented Driving to Breakthrough: Precision Medicine in Clinical Research. “Nearly 300 physicians, researchers, clinicians and leadership came together from across the Sarah Cannon network to share and discuss exciting advancements in research and care. We are proud of the great work accomplished to date, but more importantly, excited about the work ahead and how Sarah Cannon can help advance care for our patients.”
- Dee Anna Smith, Chief Executive Officer at Sarah Cannon, provided a Year in Review & What’s on the Horizon
- Tatiana Prowell, MD, Breast Cancer Scientific Liaison, Medical Officer, Office of Hematology & Oncology Products, US Food and Drug Administration; Assistant Professor, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, presented one of the two keynote presentations titled Precision Medicine as a Path to Oncology Drug Approval.
- Mark G. Kris, MD, William and Joy Ruane Chair in Thoracic Oncology, Physician Lead, Memorial Sloan Kettering- IBM Watson Collaboration, Memorial Sloan Kettering Cancer Center, also presented a keynote address titled IMPACTing Care and Research in Lung Cancers Through NSG at Diagnosis.
To see highlights from Sarah Cannon’s 21st Annual Scientific Meeting in Nashville, Tenn., watch the video below!
Sarah Cannon Research Institute is the research arm of HCA Healthcare’s global cancer institute, Sarah Cannon. Focused on advancing therapies for patients, it is one of the world’s leading clinical research organizations conducting community-based clinical trials throughout the United States and United Kingdom. Sarah Cannon’s network of strategic sites includes more than 275 physicians who engage in research. The organization has led more than 300 first-in-man clinical trials since its inception in 1993, and has been a clinical trial leader in the majority of approved cancer therapies over the last 10 years.